• In February 2026, Agilent Technologies announced that it will pay a US$0.255 quarterly dividend per share on April 22, 2026, to shareholders of record as of March 31, 2026, while also receiving U.S. FDA approval for its PD-L1 IHC 22C3 pharmDx companion diagnostic to guide first-line use of Keytruda in several hard-to-treat cancers including epithelial ovarian carcinoma.
• This latest FDA approval broadens Agilent’s role in precision oncology diagnostics, potentially deepening its integration into immunotherapy treatment pathways where effective testing is essential for treatment selection.
• We’ll now examine how the expanded FDA-approved oncology indication for PD-L1 IHC 22C3 pharmDx could influence Agilent’s existing investment narrative.

Capitalize on the AI infrastructure supercycle with our selection of the 34 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

Agilent Technologies Investment Narrative Recap

To own Agilent Technologies, you need to believe in its role as a key enabler of life sciences and diagnostics, with recurring revenues and lab automation helping offset softer instrument demand and funding pressures. The new PD-L1 IHC 22C3 indication strengthens Agilent’s precision oncology credentials but does not materially change the near term focus on managing tariff driven cost inflation and defending margins as growth has been relatively modest.

The most relevant recent announcement alongside this PD-L1 approval is Agilent’s upcoming SLAS2026 showcase of automation, AI enabled optimization, and integrated software workflows. Together, these oncology and automation updates point to the same core catalyst: expanding higher value, recurring solutions that can support earnings resilience if capital spending cycles or academic and government budgets remain under pressure.

Yet even with these advances, investors should be aware that rising tariff related costs and supply chain complexity could still...

Agilent Technologies' narrative projects $8.0 billion revenue and $1.7 billion earnings by 2028. This requires 5.8% yearly revenue growth and about a $0.5 billion earnings increase from $1.2 billion today.

Uncover how Agilent Technologies' forecasts yield a $169.67 fair value, a 35% upside to its current price.

Exploring Other Perspectives

Four Simply Wall St Community fair value estimates span roughly US$117 to US$170 per share, underscoring how widely opinions can differ. Against that backdrop, Agilent’s margin sensitivity to tariff and supply chain costs is a key factor readers may want to weigh when considering the company’s future earnings resilience.

Explore 4 other fair value estimates on Agilent Technologies - why the stock might be worth 7% less than the current price!

Build Your Own Agilent Technologies Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Agilent Technologies research is our analysis highlighting 4 key rewards that could impact your investment decision.
• Our free Agilent Technologies research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Agilent Technologies' overall financial health at a glance.

Searching For A Fresh Perspective?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

• Explore 23 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
• Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 30 best rare earth metal stocks of the very few that mine this essential strategic resource.
• Invest in the nuclear renaissance through our list of 85 elite nuclear energy infrastructure plays powering the global AI revolution.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.